SCLEROSING OF RECURRENT LYMPHANGIOMA USING OK-432

The authors present two cases of lymphangioma of the cervicofacial reg ion, treated with a new investigational drug in North America, OK-432 (picibanil), a sclerosing agent intralesionally injected. Both patient s had been treated surgically and had recurrence of the tumor. Intrale sional injection of OK-432 without aspiration was employed for the fir st patient, and after aspiration in the second patient. A change in co nsistency of the tumor, manifested by softening, was followed by marke d shrinkage. No complication either locally or systemically has occurr ed during the follow up period (10 to 16 months). In both cases, satis factory results were obtained, resulting in definite reduction in size and improvement in cosmetic appearance. The authors recommend OK-432 intralesional injection for surgically challenging lymphangioma. Their results support those of a recent Japanese study using OK-432 as scle rosing therapy for unresectable lymphangioma. Copyright (C) 1995 by W. B. Saunders Company